checkAd

    DGAP-News  281  0 Kommentare XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs

    DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous
    XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs

    10.02.2021 / 09:05
    The issuer is solely responsible for the content of this announcement.


    XPhyto Adds Mescaline Production to Psychedelic Medicine Programs

    VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that XPhyto Laboratories Inc., its wholly owned Alberta subsidiary, has added mescaline production to its psychedelic medicine programs. Further to the Company's press release dated February 3, 2021, the capacity under contract with Applied Pharmaceutical Innovation will focus on the synthesis of pharmaceutical grade mescaline. Mescaline has been anecdotally recognized as a relatively safe psychedelic drug and has shown particular promise for the treatment of addiction and depression.

    "In addition to our European-based psilocybin biotechnology production, the Company has now expanded its portfolio of psychedelic compounds to include mescaline. Our goal is to develop industrial scale production processes for the wholesale market and for incorporation into XPhyto's thin film drug delivery platforms," commented Hugh Rogers, CEO & Director. "We see a significant market opportunity in the production of pharmaceutical mescaline and the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use."

    Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic compound found in certain cacti, including peyote, San Pedro, and Peruvian torch, and is most commonly associated with traditional Native American religious rituals and ceremonies. Mescaline is a Schedule I drug in the United States; however, it is legal in certain religious ceremonies registered by the Native American Church and its use is expanding as a supplement to various types of meditation and psychedelic therapy.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs DGAP-News: XPhyto Therapeutics Corp. / Key word(s): Miscellaneous XPhyto Therapeutics Corp.: XPhyto Adds Mescaline Production to Psychedelic Medicine Programs 10.02.2021 / 09:05 The issuer is solely responsible for the content of this …